Georgia Bio Members Take Advantage of the Abundant Networking and Partnering Opportunities at BIO 2019

Georgia Bio was delighted to attend the 2019 BIO International Convention in Philadelphia from June 3rd to June 6th. During the four days of programming and exhibitions under the theme, “It Starts with One,” Georgia Bio and some of its members had the opportunity to continue their mission of advancing the growth of Georgia’s life science industry by fostering new and existing relationships with like-minded organizations. 

The 2019 BIO International Convention included 126 educational sessions, more than 800 speakers, over 250 company presentations, 1,800 exhibitors, and plenty of networking and partnering opportunities. Among the 17,300 attendees at this year’s event were both Georgia life science companies and Georgia Bio members, PainCareLabs and Recro Gainesville.

Dr. Amy Baxter, founder and CEO of PainCareLabs in Atlanta, spoke positively about her experience exhibiting at the 2019 Convention and on the support that the State of Georgia was able to provide their affiliated companies that allowed them to take full advantage of their time at the convention. 

“Georgia did everything right,” explained Baxter. “They had a gorgeous booth, offered strong support so we could focus on networking, and executed great planning in advance.

“It may seem odd to be a medical device company at a bio/pharma event, but our devices work in conjunction with pharma products to block the pain of their injections and everyone was interested in how we could make the patient journey better for their patients. The explosion in the biosimilars market means companies want a way to differentiate their product and support.” 

Amy also noted that the female to men ratio at Convention was significantly higher compared to other industry conferences that she has attended, including J.P. Morgan, and there were several female CEOs that visited their booth. This year, BIO was able to break their own Guinness World Record for “The Largest Business Partnering Event” – previously set at BIO 2018 – by participating in over 48,500 partnering meetings at this year’s convention. Gaining access to an environment that facilitates this many networking and partnering opportunities is exactly why companies like PainCareLabs look forward to attending the annual event. 

“BIO is all about deals and we were able to get our first purchase order just 7 days after the show,” said Baxter. “We would definitely attend again!”

Tara Lorenz, Senior Marketing Manager at Recro Gainesville , also expressed her company’s enthusiasm for the event and the support that was provided to Georgia organizations. 

“Many attendees were excited to see the State of Georgia represented at BIO 2019 and approached our booth to learn about Recro Gainesville’s capabilities as a Contract Drug Manufacturing Organization,” stated Lorenz.  

“By attending and exhibiting at events such as BIO 2019, we have the opportunity to learn and reflect on how recent innovations and advances in technology could have a global impact to address unmet medical needs and increase the number of approved orphan drugs and rare disease medications worldwide.”

Lorenz also elaborated on the value of events like BIO that bring together large groups of innovators who don’t normally have the opportunity to collaborate on a day-to-day basis.

“This kind of collaboration is so instrumental for sharing best practices and fostering advancement in healthcare,” she explained. “These new conversations that develop into trusted relationships could advance a new molecule all the way to FDA approval and result in novel therapies for future generations. Events like this one truly help set the stage for manufacturing and commercializing new life saving medications for patients.” 

Georgia Bio loved the opportunity to partner with the State of Georgia on the Georgia Pavilion to help drive growth for our members and Georgia’s biosciences industry at the BIO International Convention, and we are looking forward to BIO 2020 in San Diego! For more information on Georgia Bio and our mission, visit www.gabio.org or follow us on Twitter @Georgia_Bio

January 20, 2026
January 20, 2026. Paulding County has been designated a BioReady Silver Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady designation recognizes communities that demonstrate strong zoning practices, infrastructure capacity, and readiness to support biotechnology and life sciences development. “We are proud to recognize Paulding County as our newest BioReady Silver community,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Paulding County’s proactive planning, growing workforce, and access to regional healthcare and transportation infrastructure position it well to support life sciences manufacturing and commercialization. Through the BioReady program, we champion communities that are intentionally preparing to compete for industry investment and job growth.” Paulding County’s designation reflects its commitment to thoughtful land-use planning, scalable infrastructure, and business-friendly development policies that support life sciences and advanced manufacturing uses. Located in the northwest Atlanta metro region, the county offers access to a strong labor pool, major transportation corridors, and regional healthcare systems, making it an attractive option for biotechnology, medical device, diagnostics, and related life sciences companies seeking room to grow. “Georgia BioReady designation validates Paulding County’s readiness to support bioscience investment and strengthens our position as a growing hub for advanced industries,” said Alex Almodovar, President & CEO, Paulding County Economic Development Inc. & Industrial Building Authority The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-appropriate sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Paulding County to compete more effectively for private investment and high-quality job creation. Georgia Life Sciences advances innovation, strengthens the workforce pipeline, and grows Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system, which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
January 14, 2026
What happens when students see real work before choosing a future 
January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html
MORE POSTS